FIELD: pharmaceutics. SUBSTANCE: the present innovation deals with aqueous pharmaceutical compositions of erythropoietin being free of human serum products, stabilized with amino acid and derivatives of sorbitan mono-9-octadecenoate poly(oxy- 1.2-ethandiyl). The present innovation, also, deals with aqueous stable pharmaceutical erythropoietin compositions containing conservants that contain antibacterial quantities of cresol and amino acid. Pharmaceutical compositions are stable and free of human blood products, such as albumin. EFFECT: higher efficiency. 52 cl, 4 dwg, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACOKINETIC AND PHARMACODYNAMIC MODELLING IN ADMINISTRATION OF ERYTHROPOIETIN | 2000 |
|
RU2248215C2 |
| PHARMACEUTICAL COMPOSITIONS OF hGLP-1, EXENDIN-4 AND THEIR ANALOGUES | 2007 |
|
RU2419452C2 |
| TREATMENT OF NEUROLOGICAL DYSFUNCTION BY USING FRUCTOPYRANOSE AND ERYTHROPOIETIN SULFAMATES | 2002 |
|
RU2317086C2 |
| COMPOSITIONS OF LONG-ACTING INSULIN | 2011 |
|
RU2564104C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING PLASMINOGEN, AND USE THEREOF | 2015 |
|
RU2711989C2 |
| PHARMACEUTICAL COMPOSITION OF VALSARTAN | 2008 |
|
RU2487710C2 |
| COMPOSITIONS OF LONG-TERM ACTION INSULINS | 2015 |
|
RU2642662C2 |
| METHODS AND COMPOSITIONS WHICH ALLOW MODULATION OF IMMUNE RESPONSES RELATED TO ADMINISTRATION OF BIOPHARMACEUTICAL DRUG | 2014 |
|
RU2662558C2 |
| METHOD OF TREATING OSTEOPOROSIS AND COMPOSITION USED THEREIN | 2007 |
|
RU2506070C2 |
| COMBINED PHARMACEUTICAL ERYTHROPOIETIN- AND IRON-CONTAINING PREPARATIONS | 1997 |
|
RU2188033C2 |
